Breast cancer is the second leading cause of cancer death in women. About 1 in 8 women in the U.S. will develop invasive breast cancer during her lifetime. Our lab is interested in understanding altered signaling pathways that lead to breast cancer initiation and progression. Identifying and understanding these pathways will lead to development of novel therapies. Recently our lab has become interested in understanding how signaling pathways regulate metabolic reprogramming in cancer cells.

Every year approximately 200,000 new cases of breast cancer are diagnosed, and 40,000 women are expected to die from this disease in the U.S. alone. Our lab's long-term goal is to identify novel therapeutic targets for treatment of breast cancer. We are trying to understand alterations in cellular signaling pathways between normal and cancer cells and exploit these differences for possible therapeutic gain.

View Reginato Lab News

View Reginato Lab Members

IN THE MEDIA

“Advancing Cancer Research Through Innovation: Dr. Emily Esquea’s Journey From Lab To Real-world Impact - Stories Of Impact Series”
Stories of Impact, Drexel Applied Innovation (July 2024)

“Drug-Like Molecules Show Promise Against Metastatic Breast Cancer Brain Tumors”
Inside Precision Medicine (July 22, 2024)

“Drexel Team Identifies Drug-like Molecules That Show Early Success in Targeting Breast Cancer Brain Metastases”
Drexel News Blog (July 12, 2024)

Congratulations to Dr. Reginato, recipient of the 2022-2023 STAR Scholar Outstanding Mentor of the Year Award. Read more.

"Teaming Up to Fight Brain Tumors"
College of Medicine Alumni Magazine (Fall/Winter 2016)

Reginato Lab Receives 2023 PA Breast Cancer Coalition Grant